Novel treatments for novel side effects: a case report and review of baricitinib use in the treatment of chronic inflammatory demyelinating polyneuropathy caused by immune checkpoint inhibitor use
Authors:
Open Access
- 21 November 2023
- journal article
- review article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 11 (11) , e007885
Abstract
Immune checkpoint inhibitors (ICIs) have transformed the landscape of solid cancer management. These drugs carry a risk of novel side effects, which have become known as immune-related adverse events (irAEs). Traditionally, irAEs have been managed empirically with corticosteroids. A subset of these may be steroid refractory and as more evidence emerges about their distinct pathogeneses, a more tailored approach is required. Here, we report the use of a Janus kinase (JAK) inhibitor, baricitinib, in a patient with chronic inflammatory demyelinating polyneuropathy secondary to ICI use. We also review the current literature with regards to the use of these inhibitors in the management of irAEs. Modulation of the JAK pathway warrants further investigation in the targeted management of irAEs.Keywords
This publication has 11 references indexed in Scilit:
- Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of conceptJournal for ImmunoTherapy of Cancer, 2022
- Case Series of Steroid-Resistant Immune Checkpoint Inhibitor Associated Myocarditis: A Comparative Analysis of Corticosteroid and Tofacitinib TreatmentFrontiers in Pharmacology, 2021
- Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitorsLung Cancer, 2020
- A decade of immune-checkpoint inhibitors in cancer therapyNature Communications, 2020
- Tofacitinib for Refractory Immune-Related Colitis from PD-1 TherapyNew England Journal of Medicine, 2020
- IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse modelBiochemical and Biophysical Research Communications, 2017
- Janus kinase inhibitors in autoimmune diseasesAnnals of the Rheumatic Diseases, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010